Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

LCID US Equity

Lucid Group, Inc.Consumer Discretionary · Motor Vehicles & Passenger Car Bodies · CIK 1811210 · FY ends Dec 31
$5.77
-0.45 (-7.23%)
USD · as of 2026-08-18 · marketstack
3 registered studies · 0 active

Studies where LCID is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.

2 interventional · 1 observational

Held by 10 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, Holocene Advisors, LP, SUSQUEHANNA INTERNATIONAL GROUP, LLP, Balyasny Asset Management L.P., COATUE MANAGEMENT LLC, +5 more) · FINRA short interest 2.9 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed

StudyPhaseStatusInterventionsConditionsEnrollmentPrimary completionUpdated
The Effect of Auditory Interventions on Anxiety and Agitation in People With DementiaNCT05844241Cohen Mansfield Agitation IndexRandomized · Single-masked · Supportive careNot applicableCompletedOther: Music and Theta Auditory Beat Stimulation, AudiobooksMild to Moderate Dementia482023-08-02actual2023-11-22
VivaNet Study. A Multicenter Study of Confocal Reflectance Microscopy in TelemedicineNCT01385943observationalDiagnostic accuracy, in terms of sensitivity, specificity, positive and negative predictive values with respect to histopathologic diagnosis.Withdrawnsponsor's stated reason: Study not launched due to logistical issues that could not be resolved.Skin Cancer, Skin Lesions02015-12-01actual2019-11-08
In Vivo Confocal Microscopy for Pigmented Lesion DiagnosisNCT00785369To assess the diagnostic accuracy of reflectance confocal scanning laser microscopy(RCM) for melanoma diagnosis when compared to the "gold standard" histopathologic diagnosis.Non-randomized · Open-label · DiagnosticNot applicableCompletedDevice: Reflectance confocal microscopySkin Cancer, Melanoma, Lentigo Maligna441Dec 2009actual2012-10-03

Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.

Source: ClinicalTrials.gov, retrieved 2026-08-19